Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

Leukemia

Volumn 31, Issue 1, 2017, Pages 246-248

  Ruella, M ^a,b   Kenderian, S S ^a,b,c   Shestova, O ^a,b   Klichinsky, M ^a,b   Melenhorst, J J ^a,b   Wasik, M A ^a,b   Lacey, S F ^a,b   June, C H ^a,b,d   Gill, S ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRUTINIB; INTERLEUKIN 2; INTERLEUKIN 6; TISAGENLECLEUCEL T; TUMOR NECROSIS FACTOR; ANTIBODY; CYTOKINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

B LYMPHOCYTE NEOPLASM; CANCER SURVIVAL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; B CELL LYMPHOMA; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOUSE; SYNDROME; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIGENS, CD19; CYTOKINES; HETEROGRAFTS; HUMANS; LYMPHOMA, B-CELL; MICE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SYNDROME;

EID: 84990878466     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.262     Document Type: Letter

References (16)

1. Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep 2016; 11: 368-384
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Trans Med 2011; 3: 95ra73
3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517
4. Frey NV LB, Lacey SF, Grupp SA, Maude SL, Schuster SJ, Shaw P et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Am Soc Hematol 2014; ASH Meeting 2014; Abs #2296
5. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-195
6. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20: 119-122
7. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Trans Med 2014; 6: 224ra225
8. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6: 664-679
9. Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin Oncol 2016; 34(suppl): abstr 7002
10. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42
11. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516
12. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q et al. The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res 2016; 22: 2684-2696
13. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 2016; 127: 1117-1127
14. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539-2549
15. Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA 2015; 112: E966-E972
16. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123: 1957-1960.